Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 165   

Articles published

BMY 55.14 -0.60 (-1.08%)
price chart
Stock Update (NYSE:BMY): Bristol-Myers Squibb Co and Nektar Therapeutics ...
Bristol-Myers Squibb Co (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214, as a potential combination ...
Big Pharma partners with another Bay Area company in cancer immunotherapy quest  San Francisco Business Times (blog)
Bristol-Myers to test Opdivo with Nektar drug for several cancers  Reuters
A Look At Analyst Coverage On 2 Stocks Bristol-Myers Squibb Co (NYSE:BMY), U.S ...
Bristol-Myers Squibb Co (NYSE:BMY) remained bearish with a decrease -1.77% putting the price on the $55.48 per share in last trading session ended on 9/26/2016.
Analyst's Report Recap: Bristol-Myers Squibb Co (NYSE:BMY)  Post Registrar
Worth Watching Stock: Bristol-Myers Squibb Company (NYSE:BMY)  News Oracle
Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher ...
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher ...
Bristol-Myers Squibb Co (NYSE:BMY): Price Reaction History  Post Registrar
Stock Update (NYSE:BMY): Bristol-Myers Squibb Co Announces EMA Validation of ...  Smarter Analyst
Recent Analysts Ratings of Stock: Bristol-Myers Squibb Company (NYSE:BMY)
On 9/27/2016, shares of Bristol-Myers Squibb Company (NYSE:BMY) rose +0.47% in trading session and finally closed at $55.74.
Bristol-Myers Squibb Co (BMY) Could Be Due for a Bounce
The shares of drugmaker Bristol-Myers Squibb Co (NYSE:BMY) are down 1.7% at $55.82, and just hit a new annual low of $55.11, as biotechs struggle in the wake of Hillary Clinton's promise to address "excessive unjustified costs" of life-saving drugs if ...
Bristol-Myers Squibb Co (NYSE:BMY): Should It Be in Your Portfolio?  Street Report
Trending Stocks Buzzers: Bristol-Myers Squibb Co (NYSE:BMY), Synchrony ...  Post Registrar
Analyst Update: Aerie Pharmaceuticals Inc, Bristol-Myers Squibb Co, and Clovis ...
Bristol-Myers Squibb Co hit an annual low of $55.02 on Monday, continuing a downward slide that begin with an early August bear gap.
Analyst Downgrades: JPMorgan Chase & Co., Bristol-Myers Squibb Co, and Nike Inc
Analysts are weighing in on financial interest JPMorgan Chase & Co. (NYSE:JPM), drugmaker Bristol-Myers Squibb Co (NYSE:BMY), and blue-chip stock Nike Inc (NYSE:NKE).
What are analysts Suggestions on: Bristol-Myers Squibb Company (BMY)  News Oracle
Company Update (NYSE:BMY): Bristol-Myers Squibb Co Receives European ...  Smarter Analyst
This Crushing Blow Sent Bristol-Myers Squibb Co. Down 23% in August
Shares of Bristol-Myers Squibb (NYSE:BMY), a global drug developer focused on the development cancer, cardiovascular, and genetic-defined disease drugs, plunged 23% in the month of August according to data from S&P Global Market Intelligence.
Barclays Raises Target On Merck, Lowers Target On Bristol-Myers  Benzinga
Is Bristol-Myers Squibb Presenting an Opportunity?
What do Analysts Say about: Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) reported its last earnings on Oct 27 BMO (BMO = before market open, AMC= after market close).
Sadoff Investment Management LLC Reduces Stake in Bristol-Myers Squibb Co. (BMY)  BBNS
Bristol-Myers Squibb Company's (BMY): Stock's Financial Statistics  Hot Stocks Point
Price Target Analysis: Bristol-Myers Squibb Company (NYSE:BMY)
Bristol-Myers Squibb Company (NYSE:BMY) reported its last earnings on Jul 28 BMO (BMO = before market open, AMC= after market close).